Journal of Clinical Immunology

SJR Rank #1,744H-index: 123SJR: 1.802Best quartile: Q1APC: US$4,990
Journal website: aims, scope and author guidelines
Publisher

Springer

Country

United States

Type

journal

SJR by Edition

2022202500.551.11.652.2

Subject Categories

  • ImmunologyQ1
  • Immunology and AllergyQ1

Areas: Immunology and Microbiology · Medicine

Most published research topics

Immunodeficiency and Autoimmune DisordersImmune Cell Function and InteractionT-cell and B-cell ImmunologyBlood disorders and treatmentsMonoclonal and Polyclonal Antibodies ResearchPlatelet Disorders and TreatmentsImmune Response and InflammationImmunotherapy and Immune ResponsesSystemic Lupus Erythematosus ResearchCytomegalovirus and herpesvirus research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0200400600800

Documents per Year

20222025050100150200

Detailed Information

ISSN

0271-9142, 1573-2592

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

2.77

References per Document

37.55

Coverage

1981-2026

Scope

The Journal of Clinical Immunology publishes high impact papers in the area of human immunology that explore the diagnosis, pathogenesis, prognosis, or treatment of human diseases. The Journal is particularly focused on primary immunodeficiencies and related diseases. These include inborn errors of immunity, in the broad sense of the term, their underlying genotypes and their diverse phenotypes, including infection, malignancy, allergy, auto-inflammation, and autoimmunity. We consider a wide range of studies in this area, ranging from genetic discovery, clinical description, immunologic assessment, diagnostic approach, prognosis evaluation, and treatment intervention. Case reports are considered if they are truly original and are accompanied by a succinct review of the relevant medical literature and how the novel case study advances the field. The four categories of papers are detailed in the instructions to authors.

Metrics from SCImago Journal Rank 2025. View on SCImago